

Patricia M Danzon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5858800/publications.pdf>

Version: 2024-02-01

35
papers

2,630
citations

304743

22
h-index

414414

32
g-index

44
all docs

44
docs citations

44
times ranked

1553
citing authors

#	ARTICLE	IF	CITATIONS
1	Defining Elements of Value in Health Care—A Health Economics Approach: An ISPOR Special Task Force Report [3]. <i>Value in Health</i> , 2018, 21, 131-139.	0.3	321
2	The impact of price regulation on the launch delay of new drugs?evidence from twenty-five major markets in the 1990s. <i>Health Economics (United Kingdom)</i> , 2005, 14, 269-292.	1.7	275
3	Productivity in pharmaceutical—biotechnology R&D: the role of experience and alliances. <i>Journal of Health Economics</i> , 2005, 24, 317-339.	2.7	215
4	Cross-national price differences for pharmaceuticals: how large, and why?. <i>Journal of Health Economics</i> , 2000, 19, 159-195.	2.7	212
5	Differential pricing for pharmaceuticals: reconciling access, R&D and patents. <i>International Journal of Health Care Finance and Economics</i> , 2003, 3, 183-205.	1.2	194
6	International Prices And Availability Of Pharmaceuticals In 2005. <i>Health Affairs</i> , 2008, 27, 221-233.	5.2	116
7	A Health Economics Approach to US Value Assessment Frameworks—Summary and Recommendations of the ISPOR Special Task Force Report [7]. <i>Value in Health</i> , 2018, 21, 161-165.	0.3	113
8	Prices And Availability Of Pharmaceuticals: Evidence From Nine Countries. <i>Health Affairs</i> , 2003, 22, W3-521-W3-536.	5.2	108
9	Price Discrimination for Pharmaceuticals: Welfare Effects in the US and the EU. <i>International Journal of the Economics of Business</i> , 1997, 4, 301-322.	1.7	88
10	The Economics of Parallel Trade. <i>Pharmacoeconomics</i> , 1998, 13, 293-304.	3.3	84
11	Value—Based Differential Pricing: Efficient Prices for Drugs in a Global Context. <i>Health Economics (United Kingdom)</i> , 2015, 24, 294-301.	1.7	76
12	Drug Pricing and Value in Oncology. <i>Oncologist</i> , 2010, 15, 24-31.	3.7	71
13	Pharmaceutical Pricing in Emerging Markets: Effects of Income, Competition, and Procurement. <i>Health Economics (United Kingdom)</i> , 2015, 24, 238-252.	1.7	59
14	Approaches to Aggregation and Decision Making—A Health Economics Approach: An ISPOR Special Task Force Report [5]. <i>Value in Health</i> , 2018, 21, 146-154.	0.3	59
15	International Price Comparisons for Pharmaceuticals. <i>Pharmacoeconomics</i> , 1998, 14, 115-128.	3.3	54
16	Prices And Availability Of Biopharmaceuticals: An International Comparison. <i>Health Affairs</i> , 2006, 25, 1353-1362.	5.2	51
17	Objectives, Budgets, Thresholds, and Opportunity Costs—A Health Economics Approach: An ISPOR Special Task Force Report [4]. <i>Value in Health</i> , 2018, 21, 140-145.	0.3	48
18	Affordability Challenges to Value-Based Pricing: Mass Diseases, Orphan Diseases, and Cures. <i>Value in Health</i> , 2018, 21, 252-257.	0.3	47

#	ARTICLE	IF	CITATIONS
19	Reference Pricing of Pharmaceuticals for Medicare: Evidence from Germany, the Netherlands, and New Zealand. <i>Forum for Health Economics and Policy</i> , 2004, 7, 1-54.	0.8	44
20	Vaccine Supply: A Cross-National Perspective. <i>Health Affairs</i> , 2005, 24, 706-717.	5.2	39
21	Effects of Regulation on Drug Launch and Pricing in Interdependent Markets. <i>Advances in Health Economics and Health Services Research</i> , 2012, 23, 35-71.	0.2	35
22	Differential Pricing of Pharmaceuticals: Theory, Evidence and Emerging Issues. <i>Pharmacoeconomics</i> , 2018, 36, 1395-1405.	3.3	35
23	At what price?. <i>Nature</i> , 2007, 449, 176-179.	27.8	25
24	Setting Cost-Effectiveness Thresholds As A Means To Achieve Appropriate Drug Prices In Rich And Poor Countries. <i>Health Affairs</i> , 2011, 30, 1529-1538.	5.2	25
25	Dynamic competition in pharmaceuticals: cross-national evidence from new drug diffusion. <i>Managerial and Decision Economics</i> , 2007, 28, 231-250.	2.5	22
26	Vaccine Supply: Effects of Regulation and Competition. <i>International Journal of the Economics of Business</i> , 2011, 18, 239-271.	1.7	19
27	Why Sole-Supplier Vaccine Markets May Be Here To Stay. <i>Health Affairs</i> , 2005, 24, 694-696.	5.2	15
28	Pharmacy Benefit Management: Are Reporting Requirements Pro- or Anticompetitive?. <i>International Journal of the Economics of Business</i> , 2015, 22, 245-261.	1.7	12
29	Drug Pricing and Value in Oncology. <i>Recent Results in Cancer Research</i> , 2019, 213, 153-167.	1.8	7
30	Theory and Implementation of Differential Pricing for Pharmaceuticals. , 2005, , 425-456.		6
31	Alternative strategies for Medicare payment of outpatient prescription drugs--Part B and beyond. <i>American Journal of Managed Care</i> , 2005, 11, 173-80.	1.1	6
32	Closing The Doughnut Hole: No Easy Answers. <i>Health Affairs</i> , 2004, 23, W4-405-W4-408.	5.2	2
33	Regulation of Price and Reimbursement for Pharmaceuticals. , 2012, , .		1
34	Commercial Importation of Prescription Drugs in the United States: Short-Run Implications. <i>Journal of Health Politics, Policy and Law</i> , 2011, 36, 295-316.	1.9	0
35	'Responsible National Health Insurance:' The Authors Respond. <i>Health Affairs</i> , 1991, 10, 227-228.	5.2	0